News

Edwards Lifesciences (EW) reported $1.6 billion in revenue for the quarter ended March 2024, representing a year-over-year increase of 9.5%. EPS of $0.66 for the same period compares to $0.62 a year ago.

The reported revenue represents a surprise of +1.43% over the Zacks Consensus Estimate of $1.58 billion. With the consensus EPS estimate being $0.64, the EPS surprise was +3.13%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Edwards Lifesciences performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net Sales- Outside of the United States: $657.50 million compared to the $668.43 million average estimate based on three analysts. The reported number represents a change of +7.7% year over year.
• Net Sales- United States: $940.70 million compared to the $912.40 million average estimate based on three analysts. The reported number represents a change of +10.8% year over year.
• Net Sales- Japan: $110.80 million compared to the $121.77 million average estimate based on two analysts. The reported number represents a change of -2.9% year over year.
• Net Sales- Europe: $367.80 million compared to the $371.73 million average estimate based on two analysts. The reported number represents a change of +11.1% year over year.
• Net Sales- Rest of World: $178.90 million versus $176.68 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +8.2% change.
• Net Sales- Transcatheter Aortic Valve Replacement: $1.01 billion compared to the $1.02 billion average estimate based on nine analysts. The reported number represents a change of +6.3% year over year.
• Net Sales- Critical Care: $251.30 million compared to the $232.12 million average estimate based on nine analysts. The reported number represents a change of +13.3% year over year.
• Net Sales- Surgical Structural Heart: $266.10 million versus $256.03 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +7.2% change.
• Net Sales- Transcatheter Mitral and Tricuspid Therapies: $72.90 million versus the nine-analyst average estimate of $66.86 million. The reported number represents a year-over-year change of +75.2%.

View all Key Company Metrics for Edwards Lifesciences here>>>

Shares of Edwards Lifesciences have returned -6.9% over the past month versus the Zacks S&P 500 composite's -3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Free – 5 Dividend Stocks to Fund Your Retirement

Zacks Investment Research has released a Special Report to help you prepare for retirement with 5 diverse stocks that pay whopping dividends. They cut across property management, upscale outlets, financial institutions, and a couple of strong energy producers.

5 Dividend Stocks to Include in Your Retirement Strategy is packed with unconventional wisdom and insights you won’t get from your neighborhood financial planner.

Download Now – Today It’s FREE >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.